🌍December 15, 2022·Dec 15, 2022Industry

Results of a phase 2 study of praluzatamab ravtansine (CX-2009) in patients with advanced breast cancer (ABC)

Publisher

CytomX Therapeutics

Global

This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.

Read original

At a glance

Publisher: CytomX Therapeutics
Region: 最新
Scope: Industry
Published: December 15, 2022

In-platform summary, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Source route

Continue on cytomx.com

Leave the platform to read the original full article on the publisher site.

Source: CytomX Therapeutics

Scope: Industry

Open original article

Related coverage

More related coverage

SELLAS Life Sciences·21h ago

Results of a phase 2 study of praluzatamab ravtansine (CX-2009) in patients with advanced breast cancer (ABC)

More related coverage

Company - Sellas Life Sciences

WuXi AppTec’s 1260H Listing Brings the BIOSECURE Act Back to Center Stage

Update on Patient Enrollment in Phase 2 Study of Enzomenib for Acute Leukemia

Menicon and Tohoku University Develop “SilicoSim,” a Digital Simulation Platform for Next-Generation Contact Lens Materials